A Research on the Therapeutic Potential of Novel Chemical Entities Utilized in an Animal Model of Alzheimer's Disease

  • Sailesh Narayan Associate Professor, Department of Pharmacy, Usha Martin University, Ranchi- Jharkhand
  • Barun Ranjan Sarkar Assistant Professor, Department of Pharmacy, Himalayan University, Itanagar-Arunachal Pradesh
  • Dashrath Singh Professor, Department of Pharmacy, Mangalayatan University, Aligarh, Uttar Pradesh
  • Suraj Sharma Associate Professor, Collage of Pharmacy, Sikkim Professional University, Gangtok, Sikkim
Keywords: TAS-4, Alzheimer’s disease patients, toxicity, standard dopaminergic drugs

Abstract

Alzheimer’s disease is a debilitating condition that affects the nervous system. The current method of treating Alzheimer’s diseaseis ineffective at achieving long-term control of the disease and is also associated with a variety of side effects, such as dyskinesia. The development of non-dopaminergic treatments for Alzheimer’s disease(AD) is aimed at creating therapies that can improve motor deficits without the risk of the adverse chronic effects that are associated with traditional dopaminergic medications. The metabotropic glutamate receptor mGluR4, which is currently receiving attention, is one example of such a target. The activation of mGluR4 has the potential to be presented as a novel and promising treatment for Parkinson's disease. In addition, it is believed that a valid and viable treatment option for Alzheimer’s diseaseis the application of a positive allosteric modulator at the orthosteric glutamate site as opposed to the use of direct acting agonists.

References

Le Poul E, Boléa C, Girard F, Poli S, Charvin D, Campo B, Bortoli J, Bessif A, Luo B, Koser J, Hodge M, Smith M, DiLella G, Liverton N, Hess F, Browne E, Reynolds J. A Potent and Selective Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator Improves Movement in Rodent Models of Parkinson’s disease. J Pharma Eex Thera 2012: 343: 167–177

Park A, Stacy M. Disease-Modifying Drugs in Parkinson's Disease. Drugs 2015 ; 75: 2065-2071

Brooks I, Chadwick A, Gelbard A, Cory-Slechta A, Federoff J. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 1999; 823: 1-10.

Cacabelos R. Parkinson's Disease: From Pathogenesis to Pharmacogenomics. Int J Mol Sci 2017;4: 18(3)

Duty S, Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol. 2011; 164: 1357-1391.

Published
2022-11-25
How to Cite
Sailesh Narayan, Barun Ranjan Sarkar, Dashrath Singh, & Suraj Sharma. (2022). A Research on the Therapeutic Potential of Novel Chemical Entities Utilized in an Animal Model of Alzheimer’s Disease. Revista Electronica De Veterinaria, 23(4), 29 - 34. Retrieved from https://veterinaria.org/index.php/REDVET/article/view/270